GHK-Cu Dosage & Injection Protocol Guide: Complete Protocol for Safe Administration

Medically reviewed by the BHRC Clinical Team — Beverly Hills Rejuvenation Center · Written by Sam Brooks · Published / Reviewed July 24, 2026

Educational information only — not medical advice. GHK-Cu is not an FDA-approved drug. The dosing figures below describe protocols used under physician supervision at a licensed clinic; they are not self-administration instructions. GHK-Cu therapy requires a prescription and a compounded product from a 503A/503B pharmacy under a provider’s care. Do not source or inject peptides on your own.

Quick GHK-Cu Dosing Summary

For injectable copper tripeptide (GHK-Cu), the most commonly used physician-directed protocol is 1 mg subcutaneously once daily for days 1–15, increasing to 2 mg once daily for days 16–30, then a 30-day rest (30 days on / 30 days off). The practical dose range is roughly 0.5–3 mg per day. A 50 mg vial reconstituted with 2 mL of bacteriostatic water (never saline) yields 25 mg/mL, so 1 mg = 4 units and 2 mg = 8 units on a U-100 insulin syringe. Everything below is provider-directed and individualized.

Schedule a Peptide Therapy Consultation →

What Is GHK-Cu?

GHK-Cu is the copper(II)-bound form of a naturally occurring human tripeptide, glycyl-L-histidyl-L-lysine (GHK). It was first isolated from human plasma in 1973 by biochemist Loren Pickart, who noticed that the peptide fraction of blood from younger donors caused older liver tissue to behave as if it were younger. The molecule is small — three amino acids — and it holds a single copper ion with high affinity. That copper is not incidental; it is central to how the peptide works, which is exactly why the reconstitution rules later in this guide matter so much.

The GHK-Cu Molecule and Its Copper Ion

The name itself is a map of the molecule: glycine, histidine, and lysine, joined in sequence, with a copper(II) ion coordinated through the histidine imidazole and the peptide backbone. That binding geometry mirrors how the tripeptide sits in human plasma naturally, which is part of why GHK-Cu behaves like a physiologic signal rather than a foreign chemical. GHK binds copper in the same way the body’s own copper-transport systems do, allowing it to shuttle copper into and out of tissue and to act as a signaling molecule rather than a simple mineral supplement. In laboratory and gene-expression work, Pickart and Margolina reported that GHK influences a remarkably broad slice of the human genome — on the order of nearly a third of human genes shifting expression by 50% or more in cultured cells — modulating pathways tied to tissue remodeling, inflammation, and antioxidant defense.¹

Why GHK Levels Decline With Age

Plasma GHK concentrations fall substantially with age — roughly 200 ng/mL around age 20 down toward 80 ng/mL by age 60. This age-related decline is one of the central rationales offered for supplementing GHK-Cu: as endogenous levels drop, the tissue-repair and remodeling signals the peptide supports may weaken. This is a research-derived hypothesis, not a proven clinical mechanism of “reversing aging.”

What GHK-Cu Is Studied For

The best-supported human data for GHK-Cu are dermatologic and come from topical use: improvements in skin firmness, density, fine-line depth, and collagen synthesis in controlled cosmetic trials.² In one frequently cited facial-cream study, GHK-Cu applied twice daily for 12 weeks improved skin laxity, clarity, and firmness, reduced fine lines and mottled pigmentation, and increased skin density and thickness in women with photoaged skin. In a comparative thigh-skin study, GHK-Cu stimulated collagen production in roughly 70% of treated women — outperforming vitamin C and retinoic acid in that particular comparison.² Injectable, systemic GHK-Cu is used in wellness and regenerative-medicine settings for skin quality, hair support, and connective-tissue repair, but the systemic human evidence is far thinner than the topical evidence — a distinction we return to throughout this guide.

How GHK-Cu Is Thought to Work

Mechanistically, GHK-Cu is best described as a signaling molecule rather than a nutrient. Research attributes several overlapping actions to it: stimulation of collagen, elastin, and glycosaminoglycan synthesis by dermal fibroblasts; modulation of matrix metalloproteinases (the enzymes that remodel the extracellular matrix); promotion of angiogenesis (new blood-vessel formation) and nerve outgrowth; antioxidant and anti-inflammatory effects; and support for cellular “housekeeping” pathways.^1,4 In wound and tissue models, GHK-Cu has been associated with increased fibroblast proliferation, greater extracellular-matrix deposition early in healing, and metalloproteinase modulation later in the remodeling phase.⁵ The copper ion is not a passenger in any of this — it is required for the redox chemistry and copper-dependent enzyme support that underlie many of these effects, which is the biochemical reason the reconstitution rule in this guide is so strict.

GHK-Cu Dosing Protocols Based on Clinical Research

There is no FDA-approved GHK-Cu injection and therefore no official prescribing label with an approved dose. The protocols below reflect physician-directed practice patterns and are always individualized. Read them as education about how clinicians think about dosing, not as a recipe to follow at home.

Standard Dosing Ranges

The typical injectable window is 0.5–3 mg per day subcutaneously, with 1–2 mg being the most common working dose. Many providers deliberately start low — some at 200–500 mcg (0.2–0.5 mg) daily — to gauge tolerance and injection-site response before titrating upward. Higher daily doses do not have a clear evidence advantage and increase the cumulative copper load, so restraint is the norm.

It helps to keep the units straight, because dosing sources use both micrograms and milligrams. 1 mg equals 1,000 mcg, so a “500 mcg starting dose” and a “0.5 mg starting dose” are the same thing. The reason low starts are so common with GHK-Cu specifically — more than with, say, a GH secretagogue — is the copper. A conservative opening dose is not just about peptide tolerance; it is about introducing exogenous copper gradually and watching how the patient’s skin and injection sites respond before the copper load climbs over the course of an on-cycle.

Research-Based Protocols and the 30-Day Titration

The most widely referenced injectable schedule is a 30-day escalating cycle:

• Days 1–15: 1 mg once daily subcutaneously.
• Days 16–30: 2 mg once daily subcutaneously.
• Days 31–60: off (rest period).

This ramp lets the body acclimate to a lower copper load first, then steps up once tolerance is established. After a 30-day rest, the cycle can be repeated under provider guidance. Some anti-aging protocols hold a steady 1–2 mg daily throughout the on-cycle rather than escalating; both patterns are in use.

Clinical Trial Data and Its Limits

It is important to be honest about the evidence base. The controlled human trials showing measurable outcomes — increased dermal collagen, improved skin density, reduced wrinkle depth, faster healing of laser-resurfaced skin — used topical GHK-Cu creams and gels, not systemic injection.^2,3 A great deal of the regenerative and tissue-repair data (bone, liver, stomach lining, lung fibroblasts) comes from cell-culture and animal models.^1,4 An active clinical trial (NCT07437586) is evaluating topical GHK-Cu gel for acute wound healing in adults.⁵ No comparable body of controlled human trials establishes standardized systemic injection dosing — which is precisely why injectable dosing is individualized and provider-supervised.

Beginner, Intermediate, and Advanced Tiers

Advancing a tier is a clinical decision, not a personal one — it depends on tolerance, goals, copper status, and how the skin and injection sites are responding.

Dosage Chart by Goal

Different goals tend to be pursued with slightly different emphases. The chart below is an educational summary of how providers often frame GHK-Cu by objective — it is not a prescription, and every figure is individualized.

Notice that the doses do not vary dramatically by goal — the biggest levers are route (topical vs. injectable vs. both) and how the peptide is sequenced with procedures or other therapies, not radically different milligram amounts. That is consistent with GHK-Cu being a signaling peptide with a copper ceiling rather than a dose-it-higher-for-more-effect compound.

How to Reconstitute GHK-Cu

GHK-Cu ships as a lyophilized (freeze-dried) powder that must be reconstituted before use. This section is the single most important technical part of the guide, because the wrong diluent chemically inactivates the peptide.

The Critical Rule: Bacteriostatic Water, Never Saline

Reconstitute GHK-Cu only with bacteriostatic water (sterile water with 0.9% benzyl alcohol). Do not use saline (sodium chloride solution). This is the mistake competitors and DIY guides most often get wrong. GHK-Cu’s activity depends on its bound copper ion; the chloride in saline competes for and strips copper away, forming copper chloride species and degrading the intact GHK-Cu complex. Bacteriostatic water preserves the copper coordination and adds an antimicrobial preservative (benzyl alcohol) so a multi-dose vial stays usable for the ~28–30 days of a cycle. Plain sterile water can be used for a single-use vial but lacks preservative; saline should be avoided entirely.

Step-by-Step Reconstitution

1. Sanitize. Wash hands, work on a clean surface, and wipe the rubber stopper of both the GHK-Cu vial and the bacteriostatic water vial with a fresh alcohol swab.
2. Draw the diluent. Using a sterile syringe, draw the prescribed volume of bacteriostatic water (for a 50 mg vial, typically 2 mL).
3. Add slowly, down the wall. Insert the needle at an angle and let the water run slowly down the inside glass wall of the peptide vial. Do not squirt it forcefully onto the powder.
4. Swirl, don’t shake. Gently swirl or roll the vial until fully dissolved. Shaking can shear the peptide and create foam. The solution takes on a characteristic blue tint from the copper — this is expected.
5. Inspect. The solution should be clear blue with no particulates. Discard if cloudy or if particles remain.
6. Refrigerate. Store at 2–8 °C, protected from light, and label with the reconstitution date.

These steps describe how a compounded product is handled under professional guidance and are provided for patient understanding, not as instructions to compound peptides yourself.

Dosing Calculation Examples (mg to Insulin Units)

Dosing math is done on a standard U-100 insulin syringe, where 100 units = 1 mL. So each unit is 0.01 mL, and the milligrams per unit depend entirely on your concentration (mg/mL).

Worked example — 50 mg vial + 2 mL bacteriostatic water = 25 mg/mL:

• 1 mL = 25 mg, so 1 unit (0.01 mL) = 0.25 mg.
• Target 1 mg → 1 ÷ 0.25 = 4 units (0.04 mL).
• Target 2 mg → 8 units (0.08 mL).
• Target 0.5 mg → 2 units; target 3 mg → 12 units.

Formula to reuse for any concentration:

units = (desired mg ÷ concentration in mg/mL) × 100

Reconstitution & Syringe-Unit Chart (50 mg and 100 mg Vials)

Practical note: a more dilute mix (for example 50 mg in 5 mL) spreads the dose across more units, which makes small doses easier to measure accurately on the syringe. A more concentrated mix means a smaller injection volume. Your provider selects the dilution that makes your prescribed dose land on easy-to-read unit marks.

Common Reconstitution Mistakes to Avoid

• Using saline. The single biggest error. It strips copper and inactivates the peptide. Bacteriostatic water only.
• Shaking the vial. Vigorous shaking can fragment the peptide and create foam that makes drawing an accurate dose harder. Gentle swirling is enough.
• Injecting water directly onto the powder. Aim the stream at the glass wall so the diluent trickles down gently.
• Miscalculating units. The number of units for a given milligram dose changes entirely with concentration. Always recompute when the dilution changes; do not reuse a unit number from a different mix.
• Leaving the vial at room temperature or in light. Copper peptide solutions are sensitive; refrigerate and protect from light immediately after mixing.
• Using a vial past its window. Even with preservative, discard around the 28–30 day mark or sooner if the solution looks off.

GHK-Cu Administration Guide

Injectable GHK-Cu is given subcutaneously — into the fat layer just under the skin, not into muscle or vein. The first injection is typically performed or supervised in-clinic so the patient can be taught proper technique.

Injection Site Selection

Common subcutaneous sites include the lower abdomen (about two inches to either side of the navel), the outer thigh, and the back of the upper arm. Some patients using GHK-Cu for localized skin or hair goals will, under provider direction, inject nearer the target area, but the abdomen remains the standard general site. Rotate sites with each dose to avoid tissue irritation, lumps, or fat changes at any one spot.

A simple rotation habit is to move at least an inch from the previous injection and to alternate sides and regions day to day — left abdomen, right abdomen, left thigh, right thigh, and so on. Avoid injecting into skin that is bruised, broken, inflamed, tattooed over freshly, or scarred, and steer clear of the two-inch zone immediately around the navel. Consistent rotation keeps the subcutaneous tissue healthy over a full cycle and preserves reliable absorption.

Subcutaneous Injection Technique

1. Wash hands and swab the chosen site with alcohol; let it dry.
2. Draw the prescribed number of units, tapping out air bubbles.
3. Pinch a fold of skin. Insert the short insulin needle at 45–90° depending on body fat.
4. Inject slowly and steadily, then withdraw and apply light pressure with clean gauze.
5. Dispose of the needle in a sharps container. Never reuse or share needles.

What the Blue Solution and Injection Feel Like

The reconstituted solution is visibly blue because of the copper. A brief, mild stinging at the injection site is common and usually fades within seconds to minutes. Transient redness or a small bruise can occur and typically resolves within a day or two. Persistent pain, spreading redness, or warmth is not normal and should prompt a call to your provider.

Storage and Shelf Life

Storage is not an afterthought with GHK-Cu — copper peptide in solution is more delicate than many other peptides. Keep the lyophilized (unmixed) powder refrigerated or per the pharmacy’s label, protected from light and moisture, until you are ready to reconstitute; in dry powder form it is relatively stable. Once reconstituted, store the vial at 2–8 °C (36–46 °F), upright, and shielded from light. Do not freeze reconstituted solution, and do not leave it sitting out at room temperature between doses. Label the vial with the reconstitution date and use it within roughly 28–30 days; the benzyl alcohol in bacteriostatic water keeps a multi-dose vial usable across that window, but it does not extend it indefinitely. Discard early if the blue solution turns cloudy, changes color markedly, or develops particulates.

Optimal Timing for GHK-Cu Administration

GHK-Cu does not have the strict fasting and sleep-timing constraints that growth-hormone secretagogues like CJC-1295/Ipamorelin do, so timing is more flexible.

Evening Dosing and the Repair Rationale

Many providers favor evening or bedtime dosing on the rationale that the body’s tissue-repair and remodeling activity is concentrated during sleep, and GHK-Cu’s studied actions are repair-oriented. Evening dosing also lets any minor injection-site stinging settle overnight. Some clinicians suggest spacing the dose a couple of hours after the last meal, largely as a practical routine rather than a strict pharmacologic requirement — GHK-Cu does not depend on an empty stomach the way growth-hormone secretagogues do.

Consistency Over Precision

More important than the exact hour is dosing at roughly the same time each day to maintain steady exposure across the cycle. Unlike GH peptides, GHK-Cu does not require a strictly empty stomach; it can be given with or without food.

Coordinating With Procedures

Because topical GHK-Cu has data supporting recovery of resurfaced skin, some clinics time GHK-Cu use around microneedling, laser, or other skin procedures.³ Any such coordination should be planned by the treating provider, since peri-procedure protocols and copper load need to be managed deliberately.

GHK-Cu Cycle Length and Protocol Duration

Cycling is not optional cosmetic detail for GHK-Cu — it is a copper-management strategy.

The 30-On / 30-Off Standard

The default injectable cycle is 30 days on, followed by 30 days off. Every dose of GHK-Cu delivers elemental copper, and building in a rest period lets the body clear and rebalance copper stores before the next cycle. The off period also reduces the theoretical risk of the peptide’s effects plateauing. This 30/30 rhythm is the most consistent recommendation across GHK-Cu protocols precisely because it is built around the copper, not around the peptide’s half-life — it is a safety-driven schedule first and a performance-driven one second.

Why Copper Load Drives the Rest Period

At typical subcutaneous doses, the elemental copper delivered per dose is small relative to the adult recommended daily copper intake, but it accumulates over an on-cycle. Copper is essential in trace amounts and harmful in excess. The 30-day off-cycle is a conservative buffer against cumulative copper overload — a concern that is more pronounced with injectable systemic dosing than with topical use.

How Long Before Results, and How Long to Continue

Skin-quality and repair changes are gradual; patients and providers generally assess response over two to three cycles rather than within a single cycle. There is no established maximum number of cycles, but ongoing use should be paired with periodic reassessment of goals, side effects, and — where clinically indicated — copper and related mineral status.

Escalation Within a Cycle vs. Steady Dosing

Providers generally use one of two on-cycle patterns. The escalating pattern (1 mg for the first half, 2 mg for the second half) is the most commonly cited and is useful for patients new to the peptide, since it introduces copper gradually and lets tolerance guide the step-up. The steady pattern holds a fixed 1–2 mg daily throughout the on-cycle and is sometimes preferred for returning patients who already know they tolerate the higher dose. Neither pattern is universally “correct”; the choice depends on experience, goals, and how the patient responded to prior cycles. What both share is the mandatory off-cycle — the copper-management rest period is the non-negotiable part, not the exact ramp.

GHK-Cu Safety Profile and Potential Side Effects

GHK-Cu is generally well tolerated in the doses described here, but “well tolerated” is not “risk-free,” and the copper component creates specific concerns that generic peptide guides tend to gloss over.

Common Side Effects

• Injection-site reactions: redness, mild swelling, transient stinging, or small bruises — usually resolving within 24–72 hours.
• Occasional systemic effects: mild fatigue or headache reported by some users.
• Topical route: contact irritation, stinging, or — at high concentrations — a temporary bluish-green tint to the skin.
• “Copper uglies”: a term used in the skincare community for a transient breakout, purging, or irritation phase some people experience when starting copper peptides, particularly when layering topical copper peptides with strong actives. It is typically temporary, but it illustrates that “copper peptide” is not automatically gentle.

The Central Concern: Cumulative Copper

The most substantive long-term consideration with any GHK-Cu route is total copper delivered over time. Chronic copper overload can contribute to oxidative stress and, in extreme cases, liver and neurological injury. This is the real reason cycling, dose restraint, and provider supervision matter. Copper can also interact with zinc balance, so clinicians sometimes monitor or counsel on zinc status during extended use.

Contraindications

• Wilson’s disease and other disorders of copper handling (e.g., Menkes disease, MEDNIK syndrome): copper-containing therapy is contraindicated because the body cannot regulate copper normally.
• Pregnancy and breastfeeding: not recommended; safety has not been established.
• Active malignancy or significant liver disease: use only under specialist direction, given copper’s metabolic effects.
• Known hypersensitivity to the peptide or to benzyl alcohol (the preservative in bacteriostatic water).

Drug and Supplement Interactions

There are no well-characterized major drug interactions for injectable GHK-Cu, but two categories deserve attention: copper-modifying agents (copper supplements, high-dose zinc, or copper-chelating drugs such as penicillamine or trientine used in Wilson’s disease) and other high-load mineral supplements. Anyone on chelation therapy or taking copper/zinc supplements should disclose this so the provider can account for total copper balance. Athletes should also be aware of anti-doping considerations — see the candidacy section.

Putting the Copper Numbers in Perspective

Context helps here without minimizing the concern. At typical subcutaneous doses in the few-hundred-microgram to low-milligram range, the elemental copper delivered per dose is a fraction of the copper in the substance overall and is generally modest relative to the adult recommended daily copper allowance (roughly 900 mcg/day). That is reassuring for a single dose — but the operative word is cumulative. Over a 30-day on-cycle at 1–2 mg/day, the copper adds up, which is precisely why the field standardized on cycling and dose restraint rather than open-ended daily use. The takeaway is not “copper is dangerous” or “copper is trivial,” but that total copper exposure is the variable to manage, and it is managed through dose, cycle length, and — when indicated — monitoring.

Combining GHK-Cu with Other Peptides and Therapies

GHK-Cu is frequently discussed as a “repair and remodeling” peptide, which is why it is often considered alongside — not instead of — peptides that drive growth-hormone signaling, gut/tendon repair, or metabolic goals. The table below is a plain comparison, not a stacking prescription; any combination is a clinical decision.

Peptide Comparison Matrix

Why Some Clinics Pair GHK-Cu With GH Peptides

Because GHK-Cu’s studied role is tissue remodeling while GH secretagogues drive systemic growth and recovery signaling, some protocols consider them complementary — the theory being that GH peptides support the anabolic environment while GHK-Cu supports the local repair matrix. This is a rationale, not proof; evidence for specific combinations is limited, and combining peptides multiplies the safety variables that must be managed.

Two cautions apply to any GHK-Cu combination. First, never mix peptides in the same syringe or vial unless a pharmacist or provider has explicitly directed it; GHK-Cu’s copper chemistry can interact with other compounds, and co-mixing can compromise stability. Combinations are administered as separate injections. Second, stacking increases the number of things that can go wrong — more injection sites, more potential side effects, more variables to untangle if something changes. Because GHK-Cu also has a copper-load ceiling that other peptides do not, adding it to a stack means the copper budget has to be tracked on top of everything else. For these reasons, sequencing (running peptides in deliberate phases) is often cleaner than simultaneous stacking, and any multi-peptide plan should be built by the prescribing provider rather than assembled from forum protocols.

Topical Adjuncts and Procedure Pairing

GHK-Cu is one of the few peptides with genuine standalone topical evidence, so a common real-world pattern is systemic injectable GHK-Cu paired with a topical GHK-Cu cream and skin procedures, coordinated by the provider. Learn more about how BHRC sequences peptides with in-clinic treatments during a peptide therapy consultation.

Injectable vs. Topical GHK-Cu: Which Route Fits Your Goal?

Most people searching for “copper peptide” arrive from skincare content — serums, creams, “copper peptides for wrinkles.” That is a legitimate and, in fact, the best-evidenced use of GHK-Cu. Injectable GHK-Cu is a different tool for different goals. Here is the honest comparison.

Start Topical, Escalate Deliberately

For a patient whose goal is purely facial anti-aging, a topical GHK-Cu product is often the evidence-based place to start. Injectable GHK-Cu is worth discussing when goals are broader (systemic skin quality, hair, connective-tissue repair) or when topical results have plateaued — and always after a provider has weighed the copper-load tradeoffs. A clinic can help you decide which route, or combination, matches your goals rather than defaulting to the strongest option. Book a consultation to map that out.

Who Should Consider GHK-Cu Therapy?

GHK-Cu tends to interest a specific set of goals rather than being a general-purpose “everyone” peptide.

Good-Fit Goals

• Skin quality: firmness, density, fine lines, tone, and post-procedure recovery.
• Hair support: interest in follicle and scalp environment (evidence here is earlier-stage).
• Connective-tissue and wound-repair goals under medical supervision.
• Patients who want a repair-oriented peptide to complement a broader regenerative plan.

Who Should Not Use It

• Anyone with Wilson’s disease or another copper-handling disorder.
• Pregnant or breastfeeding individuals.
• People unwilling or unable to work within a supervised, prescription-and-compounding framework.
• Competitive athletes subject to anti-doping testing should confirm current status with their governing body before use; copper peptides and many peptides sit in a scrutinized category, and rules change.

The Candidacy Conversation

Candidacy is ultimately a medical determination that weighs your goals against copper status, medical history, medications, and realistic expectations about an evidence base that is strong topically and thinner systemically. That is the conversation a peptide therapy consultation is designed to have.

Setting Realistic Expectations

GHK-Cu is not a dramatic, overnight intervention, and framing it that way sets patients up for disappointment. The controlled human wins are meaningful but incremental — measurable improvements in skin firmness, density, and fine-line depth over weeks to months of consistent use. For hair, the human data are earlier-stage and should be discussed as promising rather than proven. For systemic connective-tissue repair, much of the supporting evidence is preclinical. A good candidate is someone whose goals align with what the peptide realistically does, who is comfortable operating within a supervised prescription framework, and who is willing to give the protocol multiple cycles before judging it. Someone chasing a single, rapid, transformational result is usually a poor fit.

Monitoring Progress and Adjusting Protocols

Because GHK-Cu outcomes are gradual and its main risk is cumulative, monitoring is both about tracking benefit and managing copper.

Tracking Benefit

• Skin: standardized photos, and where available, measures of skin firmness or elasticity, assessed across cycles rather than days.
• Symptom and tolerance log: injection-site response, energy, headaches, and any purging/irritation if a topical is layered.

Monitoring Safety

• Copper and related minerals: for extended or higher-dose use, providers may check copper status and consider zinc balance.
• General labs: as clinically indicated, particularly where liver health is a consideration.

Adjusting the Protocol

Adjustments — changing dose, dilution, timing, cycle length, or stopping — flow from what monitoring shows. Escalate only if tolerance is good and goals justify it; pull back if injection-site reactions, systemic symptoms, or copper concerns emerge. These are provider decisions, which is exactly why self-directed dose-chasing is discouraged.

When to Pause or Stop

There are clear signals to stop and check in with your provider rather than push through: injection-site reactions that worsen or fail to resolve, spreading redness or warmth (which can indicate infection), persistent headaches or unusual fatigue, or any new symptom that could reflect copper excess. Stopping GHK-Cu does not require a taper the way some hormones do — it can simply be discontinued — but the reason for stopping should be understood so the next decision (adjust, rest longer, or discontinue for good) is an informed one. As with every part of this protocol, that judgment belongs with the treating clinician.

Is GHK-Cu FDA-Approved? Legal & Regulatory Status (2026)

GHK-Cu is not an FDA-approved drug. There is no approved GHK-Cu injection with an official label, approved indication, or approved dose. It is widely available topically in cosmetics, but injectable GHK-Cu occupies a specific and currently shifting compounding-regulatory position.

What Changed on April 15, 2026

On April 15, 2026, the FDA announced the removal of injectable GHK-Cu — along with 11 other bulk drug substances — from the 503A “Category 2” list.⁶ This is not approval. Category 2 was the bin for substances that raised significant safety concerns for compounding; the removal here happened largely because the original nominators withdrew their nominations, not because the FDA affirmatively found these substances safe or effective. Removal moves GHK-Cu into a transitional status — no longer sitting in the Category 2 “concerns” bin, but not yet formally placed on the 503A list of bulk substances that may be used in compounding.

PCAC Review and What Comes Next

The question of whether these peptides belong on the 503A bulks list is being routed to the Pharmacy Compounding Advisory Committee (PCAC). The FDA scheduled PCAC public meetings, with GHK-Cu’s review slated to occur before the end of February 2027.⁶ Until that review concludes and the FDA acts, GHK-Cu’s compounding status remains unsettled. Regulatory status can change; the details above are stated as of July 24, 2026, and should be re-verified before relying on them.

The Legally Compliant Path

The compliant way to access injectable GHK-Cu is through a physician’s prescription filled by a licensed 503A or 503B compounding pharmacy, used under medical supervision. This matters for safety as much as legality: a compounding pharmacy produces the product under quality controls, at a verified concentration, with sterility and labeling a patient sourcing “research” powder online simply cannot confirm. Products marketed as “for research use only” are explicitly not intended for human use, are outside any medical oversight, and carry unknown purity and dosing. BHRC does not sell raw or “research use only” peptides, and this guide is not an invitation to source them independently. Provider-supervised, prescription-based, pharmacy-compounded — that is the framework this entire guide assumes.

Conclusion

GHK-Cu is one of the more scientifically interesting peptides in regenerative medicine — a naturally occurring copper-binding tripeptide with genuine, controlled human evidence behind its topical, skin-focused use and a broad preclinical repair signature. Injectable GHK-Cu extends that interest to systemic goals, using a familiar 1-mg-to-2-mg escalating, 30-on/30-off protocol, with reconstitution that hinges on one non-negotiable rule: bacteriostatic water, never saline, to protect the copper the molecule depends on. The honest picture is that systemic injectable evidence is thinner than topical evidence, the main risk is cumulative copper, and the regulatory status is unsettled and in active FDA review. All of which is why GHK-Cu belongs in a supervised, prescription-and-compounding setting rather than a DIY one. If your goals — skin quality, repair, or a broader regenerative plan — point toward GHK-Cu, the right next step is a medical evaluation.

Schedule a Peptide Therapy Consultation with BHRC →

Frequently Asked Questions About GHK-Cu Dosing

What is the standard GHK-Cu injection dosage?

The most commonly used physician-directed injectable protocol is 1 mg subcutaneously once daily for days 1–15, then 2 mg once daily for days 16–30, followed by a 30-day rest. The working range is about 0.5–3 mg per day, individualized to the patient. These figures describe supervised protocols, not self-administration instructions.

How much bacteriostatic water do I use for a 50 mg GHK-Cu vial?

A common reconstitution is 50 mg powder + 2 mL bacteriostatic water, yielding 25 mg/mL. At that concentration, 1 mg = 4 units and 2 mg = 8 units on a U-100 insulin syringe. A more dilute mix (e.g., 5 mL) makes small doses easier to measure. Your provider or compounding pharmacy specifies the exact volume.

Can I reconstitute GHK-Cu with saline?

No. Saline (sodium chloride) should not be used. The chloride competes for and strips the copper ion that GHK-Cu depends on for activity, degrading the complex. Always use bacteriostatic water, which preserves the copper coordination and adds a preservative for multi-dose use.

How do I convert a GHK-Cu dose from milligrams to insulin units?

Use: units = (desired mg ÷ concentration in mg/mL) × 100, because a U-100 insulin syringe holds 100 units per 1 mL. Example: at 25 mg/mL, a 1 mg dose = (1 ÷ 25) × 100 = 4 units. Always confirm your concentration first.

How should GHK-Cu be cycled?

The standard is 30 days on, 30 days off. Because every dose delivers copper, the rest period lets the body rebalance copper stores and reduces the risk of cumulative overload. Cycles can be repeated under provider guidance, with periodic reassessment.

What are the side effects of injectable GHK-Cu?

Most common are mild injection-site reactions — redness, swelling, stinging, or small bruises — usually resolving within 1–3 days. Occasional fatigue or headache is reported. The main long-term concern is cumulative copper load, which is why cycling and supervision matter. It is contraindicated in Wilson’s disease and other copper-handling disorders.

What are the “copper uglies”?

“Copper uglies” is a skincare-community term for a temporary purging, breakout, or irritation phase some people experience when starting copper peptides — most often with topical products layered over strong actives. It is usually transient. It is a reminder that “copper peptide” is not automatically gentle and that introducing it gradually is sensible.

How should reconstituted GHK-Cu be stored, and how long does it last?

Refrigerate reconstituted GHK-Cu at 2–8 °C, protected from light, and use it within roughly 28–30 days. The bacteriostatic-water preservative supports multi-dose use within that window. Unmixed lyophilized powder is more stable and is kept cool and dark until reconstitution. Discard any cloudy or particulate solution.

Is injectable vs. topical GHK-Cu better?

They serve different goals. Topical GHK-Cu has the strongest controlled human evidence and is ideal for facial anti-aging and post-procedure skin. Injectable GHK-Cu targets broader, systemic goals but has thinner systemic evidence and a higher copper load. For purely cosmetic facial goals, topical is often the evidence-based starting point; a provider can advise when injectable or a combination fits.

Is GHK-Cu FDA-approved, and is it legal in 2026?

It is not FDA-approved. On April 15, 2026, the FDA removed injectable GHK-Cu from the 503A Category 2 list — a transitional status change, not approval — with a PCAC review scheduled before the end of February 2027. The compliant path is a physician’s prescription compounded at a licensed 503A/503B pharmacy under supervision. Status can change; verify current standing before relying on it. (As of 2026-07-24.)

Related Resources / Related Blogs from BHRC

• AOD-9604 Peptide Therapy — modified GH fragment studied for fat metabolism.
• CJC-1295 / Ipamorelin — growth-hormone-supporting peptide combination often discussed alongside repair peptides.
• Tesamorelin — GHRH analog for visceral fat and metabolic goals.
• MOTS-c — mitochondrial-derived metabolic peptide.
• Start Your Journey — book a peptide therapy consultation with a BHRC medical provider.

About the Author and Medical Reviewer

Sam Brooks is a health and wellness writer at Beverly Hills Rejuvenation Center specializing in peptide therapy, regenerative medicine, and hormone optimization. He translates clinical research into plain-English patient education and works closely with BHRC’s medical team to ensure every guide reflects current protocols and evidence.

About the medical review: This guide was reviewed by the clinical team at Beverly Hills Rejuvenation Center — board-certified physicians and licensed medical providers who oversee BHRC’s medical protocols and review its clinical education for accuracy, safety, and compliance. Reviewed July 24, 2026. This content is educational and does not replace an individual medical evaluation; peptide therapy at BHRC is physician-supervised.

References

1. Pickart L, Margolina A. Regenerative and Protective Actions of the GHK-Cu Peptide in the Light of the New Gene Data. Int J Mol Sci. 2018;19(7):1987. doi:10.3390/ijms19071987. PMID: 29986520. PMC6073405
2. Pickart L, Margolina A. Skin Regenerative and Anti-Cancer Actions of Copper Peptides. Cosmetics. 2018;5(2):29. doi:10.3390/cosmetics5020029. Full text
3. Effects of Topical Copper Tripeptide Complex on CO2 Laser–Resurfaced Skin. Arch Facial Plast Surg. 2006;8(4):252–259. doi:10.1001/archfaci.8.4.252. Abstract
4. Pickart L, Vasquez-Soltero JM, Margolina A. The Human Tripeptide GHK-Cu in Prevention of Oxidative Stress and Degenerative Conditions of Aging: Implications for Cognitive Health. Oxid Med Cell Longev. 2012;2012:324832. doi:10.1155/2012/324832. PMID: 22666519. PMC3359723
5. Effects of topical copper tripeptide complex on wound healing in an irradiated rat model. PubMed. PMID: 23744835. PubMed
6. U.S. FDA. Removal of 12 substances (including injectable GHK-Cu) from the 503A Category 2 list and scheduling of PCAC meetings, April 15, 2026. Regulatory summary: Orrick analysis. Related trial (topical GHK-Cu, wound healing): ClinicalTrials.gov NCT07437586.

This content is for educational purposes only and does not constitute medical advice, diagnosis, or treatment, and does not create a physician–patient relationship. GHK-Cu is not FDA-approved. Any peptide therapy should be undertaken only under the supervision of a licensed medical provider using a prescription product compounded at a licensed 503A/503B pharmacy. Do not self-administer peptides. Regulatory statements are current as of July 24, 2026 and are subject to change.